Emibetuzumab

Emibetuzumab (INN[1]) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer.[2] It is in phase II trials for patients with NSCLC[3]

Emibetuzumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
TargetHGFR
Clinical data
Other namesLY2875358
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6356H9810N1694O2014S48
Molar mass143719.12 g·mol−1

This drug was developed by Eli Lilly & Company.

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.